Opportunities and challenges for human papillomavirus vaccination in China

References

• Okunade KS. Human papillomavirus and cervical cancer. J Obstet Gynaecol. 2020;40(5):602–11. doi:10.1080/01443615.2019.1634030.
   PubMedGoogle Scholar
• Gultekin M, Ramirez PT, Broutet N, Hutubessy R. World Health Organization call for action to eliminate cervical cancer globally. Int J Gynecologic Cancer. 2020;30(4):426–7. doi:10.1136/ijgc-2020-001285.
   PubMed Web of Science ®Google Scholar
• Illah O, Olaitan A. Updates on HPV vaccination. Diagno (Basel). 2023;13(2):243. doi:10.3390/diagnostics13020243.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Human Papillomavirus (HPV) vaccination: what everyone should know. 2021. https://www.cdc.gov/vaccines/vpd/hpv/public/index.html.
   Google Scholar
• World Health Organization. List of prequalified vaccines. 2023. https://extranet.who.int/pqweb/vaccines/list-prequalified-vaccines.
   Google Scholar
• Li M, Zhao C, Zhao Y, Li J, Wei L. Immunogenicity, efficacy, and safety of human papillomavirus vaccine: data from China. Front Immunol. 2023;14:1112750. doi:10.3389/fimmu.2023.1112750.
   PubMed Web of Science ®Google Scholar
• Shu Y, Yu Y, Ji Y, Zhang L, Li Y, Qin H, Huang Z, Ou Z, Huang M, Shen Q, et al. Immunogenicity and safety of two novel human papillomavirus 4- and 9-valent vaccines in Chinese women aged 20–45 years: a randomized, blinded, controlled with Gardasil (type 6/11/16/18), phase III non-inferiority clinical trial. Vaccine. 2022;40(48):6947–55. doi:10.1016/j.vaccine.2022.10.022.
   PubMed Web of Science ®Google Scholar
• Chu K, Bi ZF, Huang WJ, Li YF, Zhang L, Yang CL, Jiang H-M, Zang X, Chen Q, Liu D-L, et al. Safety and immunogenicity of an Escherichia coli-produced 9-valent human papillomavirus L1 virus-like particle vaccine (types 6/11/16/18/31/33/45/52/58) in healthy adults: an open-label, dose-escalation phase 1 clinical trial. Lancet Reg Health West Pac. 2023;34:100731. doi:10.1016/j.lanwpc.2023.100731.
   PubMedGoogle Scholar
• Globocan. China factsheet. 2020. https://gco.iarc.fr/today/data/factsheets/populations/160-china-fact-sheets.pdf.
   Google Scholar
• Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R, Li L, Wei W, He J. Cancer incidence and mortality in China, 2016. J Natl Cancer Cent. 2022;2(1):1–9. doi:10.1016/j.jncc.2022.02.002.
   Google Scholar
• Yuan MW, Wang HH, Duan RF, Xu KP, Hu SY, Qiao YL, Zhang Y, Zhao F. Analysis on cancer incidence and mortality attributed to human papillomavirus infection in China, 2016. Zhonghua Liu Xing Bing Xue Za Zhi. 2022;43(5):702–8. doi:10.3760/cma.j.cn112338-20211010-00777.
   PubMedGoogle Scholar
• Liu Y, Li Z, Yuan L, Liu F, Wu K, Xiao X, Zhu C. Human papillomavirus genotypic characteristics of 60,685 subjects under age-expansion vaccination of the nine-valent human papillomavirus vaccine: a cross-sectional study. J Infect Public Health. 2023;16(7):989–95. doi:10.1016/j.jiph.2023.04.018.
   PubMed Web of Science ®Google Scholar
• Zheng LL, Chen SF, Yang F, Wang WH, Xu C, Zheng LY. High-risk HPV prevalence and genotype distribution among women in Liaocheng, Shandong Province, China from 2016 to 2022. Front Public Health. 2023;11:1145396. doi:10.3389/fpubh.2023.1145396.
   PubMed Web of Science ®Google Scholar
• Yang X, Li Y, Tang Y, Li Z, Wang S, Luo X, He T, Yin A, Luo M. Cervical HPV infection in Guangzhou, China: an epidemiological study of 198,111 women from 2015 to 2021. Emerg Microbes Infect. 2023;12(1):e2176009. doi:10.1080/22221751.2023.2176009.
   PubMed Web of Science ®Google Scholar
• Lan Z, Zhang J, Li H, He R, Zhao Q, Yang F. Prevalence of human papillomavirus genotypes and related cervical morphological results in southern Hunan Province of China, 2018–2020: baseline measures at a tertiary institution prior to mass human papillomavirus vaccination. Front Microbiol. 2022;13:1094560. doi:10.3389/fmicb.2022.1094560.
   PubMed Web of Science ®Google Scholar
• Zhang W, Guo N, Li B, Shang E, Wang J, Zhang M, Yang X. Prevalence and genotype distribution of human papillomavirus infections in Beijing, China between 2016 and 2020. Virol J. 2023;20(1):11. doi:10.1186/s12985-023-01959-7.
   PubMed Web of Science ®Google Scholar
• Zhang M, Chen G, Dai X, Wu Z, Huang H, Zheng Y. Prevalence of human papillomavirus in Wenzhou, China: a cross-sectional study of 127 938 outpatient women. BMJ Open. 2022;12(12):e066698. doi:10.1136/bmjopen-2022-066698.
   PubMed Web of Science ®Google Scholar
• Chen Z, Lin H, Zheng J, Cai L, Chen Z, Li J, Yu L. Epidemiological study of HPV infection in 40,693 women in Putian: a population study based on screening for high-risk HPV infection. BMC Infect Dis. 2022;22(1):893. doi:10.1186/s12879-022-07893-3.
   PubMed Web of Science ®Google Scholar
• Li X, Xiang F, Dai J, Zhang T, Chen Z, Zhang M, Wu R, Kang X. Prevalence of cervicovaginal human papillomavirus infection and genotype distribution in Shanghai, China. Virol J. 2022;19(1):146. doi:10.1186/s12985-022-01879-y.
   PubMed Web of Science ®Google Scholar
• Huang W, Xu H, Hu H, Zhang D, Liu Y, Guo Y, Xiao F, Chen W, Ma Z. The prevalence of human papillomavirus among women in northern Guangdong Province of China. Sci Rep. 2022;12(1):13353. doi:10.1038/s41598-022-17632-y.
   PubMed Web of Science ®Google Scholar
• Liu M, Zhang X, Guo L, Sun W, Jiang X. HPV prevalence and genotype distribution among 38 056 women in Weifang, China: a cross-sectional study. BMJ Open. 2023;13(9):e073332. doi:10.1136/bmjopen-2023-073332.
   PubMed Web of Science ®Google Scholar
• Huiyun J, Jie D, Huan W, Yuebo Y, Xiaomao L. Prevalence and characteristics of cervical human papillomavirus genotypes and cervical lesions among 58630 women from Guangzhou, China. J Infect Public Health. 2023;16(10):1531–6. doi:10.1016/j.jiph.2023.07.013.
   PubMed Web of Science ®Google Scholar
• Wang T, Luan L, Deng J, Liu N, Wu Q, Gong T, Zhu J, Zhang Z, Zhang J. Prevalence and human papillomavirus (HPV) genotype distribution in Suzhou, China. Hum Vaccin Immunother. 2023;19(2):2241309. doi:10.1080/21645515.2023.2241309.
   PubMed Web of Science ®Google Scholar
• Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202(12):1789–99. doi:10.1086/657321.
   PubMed Web of Science ®Google Scholar
• Li L, Jiang M, Li T, Yin J, Feng R, Dong L, Imam S, Cui J, Liu B, Zhang X, et al. Absolute risk and attributable fraction of type-specific human papillomavirus in cervical cancer and precancerous lesions—a population-based study of 6286 women in rural areas of China. J Clin Med. 2022;11(21):6483. doi:10.3390/jcm11216483.
   PubMed Web of Science ®Google Scholar
• Castellsagué X, Díaz M, de Sanjosé S, Muñoz N, Herrero R, Franceschi S, Peeling RW, Ashley R, Smith JS, Snijders PJF, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Nat Cancer Inst. 2006;98(5):303–15. doi:10.1093/jnci/djj067.
   PubMed Web of Science ®Google Scholar
• Bruni L, Albero G, Serrano B, Mena M, Collado JJ, Gomez D, et al. ICO/IARC information centre on HPV and cancer (HPV information centre). Human papillomavirus and related diseases in China. Summary Report 10 March 2023; 2023.
   Google Scholar
• Bao H, Chen W, Zhang X, Bi H, Zhao Y, Fang L, Cong S, Tan F, Wang L. Prevalence of high-risk human papillomavirus in cervical intraepithelial neoplasia in the pre-vaccine era — China, 2017–2018. China CDC Wkly. 2022;4(48):1083–7. doi:10.46234/ccdcw2022.218.
   PubMedGoogle Scholar
• Ruan Y, Li H, Liu M, Cao G, Xu X, Han L, et al. A retrospective analysis of human papillomavirus (HPV) prevalence and genotype distribution among 25,238 women in Shanghai, China revealed the limitations of current HPV-based screening and HPV vaccine. Cancer Epidemiol. 2023;84:102372. doi:10.1016/j.canep.2023.102372.
   PubMed Web of Science ®Google Scholar
• Zhong F, Li Z, Sun Y, Xiao Y, Li J, Zhou X, Cong Q, Sui L, Tao X, Zhao C, et al. HPV genotyping of cervical histologic specimens of 61, 422 patients from the largest women hospital in China. Front Oncol. 2023;13:1161631. doi:10.3389/fonc.2023.1161631.
   PubMed Web of Science ®Google Scholar
• Tang X, Jones TE, Jiang W, Austin M, He Y, Li L, Tong L, Wang C, Yang K, Yin R, et al. Extended human papillomavirus genotype distribution in cervical intraepithelial neoplasia and cancer: analysis of 40 352 cases from a large academic gynecologic center in China. J Med Virol. 2023;95(1):e28302. doi:10.1002/jmv.28302.
   PubMed Web of Science ®Google Scholar
• Shen Y, Huang Y, Wang W, Zhang J, Chen X, Zhang L, et al. Prevalence and genotype distribution of HPV infection among women in Xiamen, China. Front Microbiol. 2023;14:1130226. doi:10.3389/fmicb.2023.1130226.
   PubMed Web of Science ®Google Scholar
• Zhang R, Hong G, Liao C, Chen Z, Lin H, Yu L. High-risk human papillomavirus infection in Putian, China: a cross-sectional analysis of 98085 women. J Coll Physicians Surg Pak. 2023;33:642–6.
   PubMed Web of Science ®Google Scholar
• Ma Y, Xia X, Zheng W, Dai Y, Zhuang X. HPV prevalence and genotype distribution among women in eastern China during the covid-19 pandemic. Hum Vaccin Immunother. 2023;19(1):2212571. doi:10.1080/21645515.2023.2212571.
   PubMed Web of Science ®Google Scholar
• Gong P, Shi B, Cong X, Yang L, Gong C, Zhou Y, Li X, Wang J. Multiple infections containing the top five prevalent HPV genotypes and their impact on cervical lesions in Changzhou, China. Hum Vaccin Immunother. 2023;19(2):2245723. doi:10.1080/21645515.2023.2245723.
   PubMed Web of Science ®Google Scholar
• Du LF, Ma ZJ, Jin YQ, Zhang XF, Zhang H, Zhang J, et al. Retrospective analysis of human papillomavirus infection among women in mainland China. 2021;41(12):954–61.
   Google Scholar
• Bruni L, Albero G, Serrano B, Mena M, Collado JJ, Gomez D, et al. ICO/IARC information centre on HPV and cancer (HPV information centre). Human papillomavirus and related diseases in the world. Summary Report 10 March 2023; 2023.
   Google Scholar
• Hildesheim A, Wacholder S, Catteau G, Struyf F, Dubin G, Herrero R. Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. Vaccine. 2014;32(39):5087–97. doi:10.1016/j.vaccine.2014.06.038.
   PubMed Web of Science ®Google Scholar
• Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, Skinner SR, Apter D, Naud P, Salmerón J, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):89–99. doi:10.1016/S1470-2045(11)70286-8.
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301–14. doi:10.1016/S0140-6736(09)61248-4.
   PubMed Web of Science ®Google Scholar
• Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007;369(9576):1861–8. doi:10.1016/S0140-6736(07)60852-6.
   PubMed Web of Science ®Google Scholar
• Future II study group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915–27. doi:10.1056/NEJMoa061741.
   PubMed Web of Science ®Google Scholar
• Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, Bartholomew D, Cestero RM, Fedrizzi EN, Hirschberg AL, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial. Lancet. 2017;390(10108):2143–59. doi:10.1016/S0140-6736(17)31821-4.
   PubMed Web of Science ®Google Scholar
• Garland SM, Pitisuttithum P, Ngan HYS, Cho CH, Lee CY, Chen CA, Yang YC, Chu TY, Twu NF, Samakoses R, et al. Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine: subgroup analysis of participants from Asian countries. J Infect Dis. 2018;218(1):95–108. doi:10.1093/infdis/jiy133.
   PubMed Web of Science ®Google Scholar
• Zhu FC, Hu SY, Hong Y, Hu YM, Zhang X, Zhang YJ, Pan Q-J, Zhang W-H, Zhao F-H, Zhang C-F, et al. Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: end-of-study results from a phase II/III, randomised, controlled trial. Cancer Med. 2019;8(14):6195–211. doi:10.1002/cam4.2399.
   PubMed Web of Science ®Google Scholar
• Zhao FH, Wu T, Hu YM, Wei LH, Li MQ, Huang WJ, Chen W, Huang S-J, Pan Q-J, Zhang X, et al. Efficacy, safety, and immunogenicity of an Escherichia coli-produced human papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial. Lancet Infect Dis. 2022;22(12):1756–68. doi:10.1016/S1473-3099(22)00435-2.
   PubMed Web of Science ®Google Scholar
• Li J, Shi L-W, Yu B-W, Huang L-R, Zhou L-Y, Shi L, Jiang Z-W, Xia J-L, Wang X-Y, Li R-C, et al. Safety and immunogenicity of a pichia pastoris-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine in healthy Chinese women aged 9–45 years: a randomized, double-blind, placebo-controlled phase 1 clinical trial. Vaccine. 2023;41(19):3141–9. doi:10.1016/j.vaccine.2023.04.009.
   PubMed Web of Science ®Google Scholar
• Walvax Yuxi Zerun Biotechnology Co. Ltd. Package insert: recombinant human papillomavirus bivalent (Types 16, 18) Vaccine (Pichia pastoris). 2022. https://en.walvax.com/media/upload/product/Package%20Insert%20of%20HPV2.pdf.
   Google Scholar
• Li R, Li Y, Radley D, Liu Y, Huang T, Sings HL, Zhang L, Wang W, Zhong X, Saah AJ, et al. Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, double-blind, placebo-controlled trial in Chinese males and females. Vaccine. 2012;30(28):4284–91. doi:10.1016/j.vaccine.2012.02.079.
   PubMed Web of Science ®Google Scholar
• Wei L, Xie X, Liu J, Zhao Y, Chen W, Zhao C, Wang S, Liao X, Shou Q, Qiu Y, et al. Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: a randomized, placebo-controlled trial with 78-month follow-up. Vaccine. 2019;37(27):3617–24. doi:10.1016/j.vaccine.2018.08.009.
   PubMed Web of Science ®Google Scholar
• Chen W, Zhao Y, Xie X, Liu J, Li J, Zhao C, Wang S, Liao X, Shou Q, Zheng M, et al. Safety of a quadrivalent human papillomavirus vaccine in a phase 3, randomized, double-blind, placebo-controlled clinical trial among Chinese women during 90 months of follow-up. Vaccine. 2019;37(6):889–97. doi:10.1016/j.vaccine.2018.12.030.
   PubMed Web of Science ®Google Scholar
• Chen M, Li C, Cui Q, Zhou C, Chen P, Yao S. The efficacy of human papillomavirus prophylactic vaccination after conization in preventing cervical intraepithelial neoplasia recurrence: a prospective observational study in China. Eur J Obstet Gynecol Reprod Biol. 2023;286:10–5. doi:10.1016/j.ejogrb.2023.04.014.
   PubMed Web of Science ®Google Scholar
• Lv H, Wang S, Liang Z, Yu W, Yan C, Chen Y, Hu X, Fu R, Zheng M, Group T, et al. Immunogenicity and safety of the 9-valent human papillomavirus vaccine in Chinese females 9–45 years of age: a phase 3 open-label study. Vaccine. 2022;40(23):3263–71. doi:10.1016/j.vaccine.2022.02.061.
   PubMed Web of Science ®Google Scholar
• Guo J, Guo S, Dong S. Efficacy, immunogenicity and safety of HPV vaccination in Chinese population: a meta-analysis. Front Public Health. 2023;11:1128717. doi:10.3389/fpubh.2023.1128717.
   PubMed Web of Science ®Google Scholar
• Zhao F, Jastorff A, Hong Y, Hu S, Chen W, Xu X, Zhu Y, Zhu J, Zhang X, Zhang W, et al. Safety of AS04-HPV-16/18 vaccine in Chinese women aged 26 years and older and long-term protective effect in women vaccinated at age 18–25 years: a 10-year follow-up study. Asia Pac J Clin Oncol. 2022;19:458–67. doi:10.1111/ajco.13833.
   PubMed Web of Science ®Google Scholar
• Porras C, Tsang SH, Herrero R, Guillén D, Darragh TM, Stoler MH, Hildesheim A, Wagner S, Boland J, Lowy DR, et al. Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica vaccine trial. Lancet Oncol. 2020;21(12):1643–52. doi:10.1016/S1470-2045(20)30524-6.
   PubMed Web of Science ®Google Scholar
• Lehtinen M, Lagheden C, Luostarinen T, Eriksson T, Apter D, Bly A, Gray P, Harjula K, Heikkilä K, Hokkanen M, et al. Human papillomavirus vaccine efficacy against invasive, HPV-positive cancers: population-based follow-up of a cluster-randomised trial. BMJ Open. 2021;11(12):e050669. doi:10.1136/bmjopen-2021-050669.
   PubMed Web of Science ®Google Scholar
• Kjaer SK, Nygård M, Sundström K, Dillner J, Tryggvadottir L, Munk C, Berger S, Enerly E, Hortlund M, Ágústsson ÁI, et al. Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four Nordic countries. EClinicalMedicine. 2020;23:100401. doi:10.1016/j.eclinm.2020.100401.
   PubMedGoogle Scholar
• Maldonado I, Plata M, Gonzalez M, Correa A, Nossa C, Giuliano AR, Joura EA, Ferenczy A, Ronnett BM, Stoler MH, et al. Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27–45 years. Hum Vaccin Immunother. 2022;18(5):2078626. doi:10.1080/21645515.2022.2078626.
   PubMed Web of Science ®Google Scholar
• Zhao C, Zhao Y, Li J, Li M, Su Y, Mi X, La Tu SY, Shen D, Ren L, Li Y, et al. The eight-year long-term follow-up on the effectiveness of the quadrivalent human papillomavirus vaccine in Chinese women 20-45 years of age. Hum Vaccin Immunother. 2022;18(5):2052700. doi:10.1080/21645515.2022.2052700.
   PubMed Web of Science ®Google Scholar
• Ferris DG, Samakoses R, Block SL, Lazcano-Ponce E, Restrepo JA, Mehlsen J, Chatterjee A, Iversen O-E, Joshi A, Chu J-L, et al. 4-Valent Human Papillomavirus (4vHPV) vaccine in preadolescents and adolescents after 10 years. Pediatrics. 2017;140(6). doi:10.1542/peds.2016-3947.
   PubMed Web of Science ®Google Scholar
• Restrepo J, Herrera T, Samakoses R, Reina JC, Pitisuttithum P, Ulied A, Bekker L-G, Moreira ED, Olsson S-E, Block SL, et al. Ten-year follow-up of 9-valent human papillomavirus vaccine: immunogenicity, effectiveness, and safety. Pediatrics. 2023;152(4). doi:10.1542/peds.2022-060993.
   PubMed Web of Science ®Google Scholar
• Kjaer SK, Nygård M, Sundström K, Munk C, Berger S, Dzabic M, Fridrich KE, Waldstrøm M, Sørbye SW, Bautista O, et al. Long-term effectiveness of the nine-valent human papillomavirus vaccine in Scandinavian women: interim analysis after 8 years of follow-up. Hum Vaccin Immunother. 2021;17(4):943–9. doi:10.1080/21645515.2020.1839292.
   PubMed Web of Science ®Google Scholar
• Drolet M, Bénard É, Pérez N, Brisson M, Ali H, Boily M-C, Baldo V, Brassard P, Brotherton JML, Callander D, et al. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019;394(10197):497–509. doi:10.1016/S0140-6736(19)30298-3.
   PubMed Web of Science ®Google Scholar
• Wang WV, Kothari S, Skufca J, Giuliano AR, Sundström K, Nygård M, Koro C, Baay M, Verstraeten T, Luxembourg A, et al. Real-world impact and effectiveness of the quadrivalent HPV vaccine: an updated systematic literature review. Expert Rev Vaccines. 2022;21(12):1799–817. doi:10.1080/14760584.2022.2129615.
   PubMed Web of Science ®Google Scholar
• Rebolj M, Pesola F, Mathews C, Mesher D, Soldan K, Kitchener H. The impact of catch-up bivalent human papillomavirus vaccination on cervical screening outcomes: an observational study from the English HPV primary screening pilot. Br J Cancer. 2022;127(2):278–87. doi:10.1038/s41416-022-01791-w.
   PubMed Web of Science ®Google Scholar
• Steben M, Tan Thompson M, Rodier C, Mallette N, Racovitan V, DeAngelis F, Stutz M, Rampakakis E. A review of the impact and effectiveness of the quadrivalent human papillomavirus vaccine: 10 years of clinical experience in Canada. J Obstet Gynaecol Can. 2018;40(12):1635–45. doi:10.1016/j.jogc.2018.05.024.
   PubMed Web of Science ®Google Scholar
• Baldur-Felskov B, Dehlendorff C, Munk C, Kjaer SK. Early impact of human papillomavirus vaccination on cervical neoplasia–nationwide follow-up of young Danish women. J Natl Cancer Inst. 2014;106(3):djt460. doi:10.1093/jnci/djt460.
   PubMed Web of Science ®Google Scholar
• Hariri S, Bennett NM, Niccolai LM, Schafer S, Park IU, Bloch KC, Unger ER, Whitney E, Julian P, Scahill MW, et al. Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States – 2008–2012. Vaccine. 2015;33(13):1608–13. doi:10.1016/j.vaccine.2015.01.084.
   PubMed Web of Science ®Google Scholar
• Lei J, Ploner A, Elfström KM, Wang J, Roth A, Fang F, Sundström K, Dillner J, Sparén P. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020;383(14):1340–8. doi:10.1056/NEJMoa1917338.
   PubMed Web of Science ®Google Scholar
• Falcaro M, Castañon A, Ndlela B, Checchi M, Soldan K, Lopez-Bernal J, Elliss-Brookes L, Sasieni P. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet. 2021;398(10316):2084–92. doi:10.1016/S0140-6736(21)02178-4.
   PubMed Web of Science ®Google Scholar
• Amend KL, Turnbull B, Zhou L, Marks MA, Velicer C, Saddier P, Seeger JD. Safety of 4-valent human papillomavirus vaccine in males: a large observational post-marketing study. Hum Vaccin Immunother. 2022;18(5):2073750. doi:10.1080/21645515.2022.2073750.
   PubMed Web of Science ®Google Scholar
• Bonaldo G, Vaccheri A, D’Annibali O, Motola D. Safety profile of human papilloma virus vaccines: an analysis of the US vaccine adverse event reporting system from 2007 to 2017. Br J Clin Pharmacol. 2019;85(3):634–43. doi:10.1111/bcp.13841.
   PubMed Web of Science ®Google Scholar
• Pan X, Lv H, Chen F, Wang Y, Liang H, Shen L, Chen Y, Hu Y. Analysis of adverse events following immunization in Zhejiang, China, 2019: a retrospective cross-sectional study based on the passive surveillance system. Hum Vaccines Immunother. 2021;17(10):3823–30. doi:10.1080/21645515.2021.1939621.
   PubMed Web of Science ®Google Scholar
• Meng R, Ma R, Wang J, Liu P, Liu Z, He B, Liu Z, Yang Y, Zhan S. Post-marketing surveillance for the safety of the 9-valent human papillomavirus vaccine: a retrospective real-world study in China. Expert Rev Vaccines. 2023;22(1):696–703. doi:10.1080/14760584.2023.2239911.
   PubMed Web of Science ®Google Scholar
• Wang H, Jiang Y, Wang Q, Lai Y, Holloway A. The status and challenges of HPV vaccine programme in China: an exploration of the related policy obstacles. BMJ Glob Health. 2023;8(8):e012554. doi:10.1136/bmjgh-2023-012554.
   PubMed Web of Science ®Google Scholar
• Wei L, Xie X, Liu J, Qiao Y, Zhao F, Wu T, Zhang J, Ma D, Kong B, Chen W, et al. Elimination of cervical cancer: challenges promoting the HPV vaccine in China. Indian J Gynecol Oncol. 2021;19(3):51. doi:10.1007/s40944-021-00536-6.
   PubMed Web of Science ®Google Scholar
• Hu S, Xu X, Zhang Y, Liu Y, Yang C, Wang Y, Wang Y, Yu Y, Hong Y, Zhang X, et al. A nationwide post-marketing survey of knowledge, attitude and practice toward human papillomavirus vaccine in general population: implications for vaccine roll-out in mainland China. Vaccine. 2021;39(1):35–44. doi:10.1016/j.vaccine.2020.11.029.
   PubMed Web of Science ®Google Scholar
• Zi WR, Yang QY, Su J, Xie JA. The research development of inoculation safety associated with licensed HPV vaccines in China. Chin J Pharmacovig. 2023;20(3):311–316. doi:10.19803/j.1672-8629.20211075.
   Google Scholar
• Action plan for accelerating the elimination of cervical cancer (2023–2030). 2023. https://www.gov.cn/zhengce/zhengceku/2023-01/21/content_5738364.htm.
   Google Scholar
• New government plan to speed up elimination of cervical cancer. 2023. http://english.www.gov.cn/policies/policywatch/202302/08/content_WS63e30acdc6d0a757729e681d.html.
   Google Scholar
• Hainan girls of appropriate age receive free HPV vaccine. China News Network; 2022 Mar 12 [accessed 2023 Nov]. https://baijiahao.baidu.com/s?id=1727072112419925717&wfr=spider&for=pc.
   Google Scholar
• Fujian Province launches free HPV vaccination program for women of appropriate age. Fujian Provincial Health Commission; 2022 May 12 [accessed 2023 Nov]. https://wjw.fujian.gov.cn/jggk/csxx/fyjkfwc/fyggws/202205/t20220512_5909168.htm.
   Google Scholar
• Our province launches free HPV vaccination for girls of appropriate age. Nanfang Daily Online Edition; 2022 Sept 8 [accessed 2023 Nov]. http://www.gd.gov.cn/gdywdt/bmdt/content/post_4009524.html.
   Google Scholar
• Chongqing will vaccinate 180,000 second-year junior high school girls with HPV vaccine for free this year. Chongqing Daily; 2023 Feb 14 [accessed 2023 Nov]. https://www.cq.gov.cn/ywdt/jrcq/202302/t20230214_11600350.html.
   Google Scholar
• Girls of appropriate age can receive free HPV vaccine starting from September. Jiangxi Provincial Health Commission; 2023 Mar 13 [accessed 2023 Nov]. http://hc.jiangxi.gov.cn/art/2023/3/13/art_38023_4387151.html
   Google Scholar
• Jiangsu deploys HPV vaccination for girls of appropriate age. Health News; 2023 Mar 23 [accessed 2023 Nov]. https://www.jkb.com.cn/news/industryNews/2023/0323/488610.html
   Google Scholar
• Zhonghua Yu Fang Yi Xue Za Zhi. Expert consensus on immunological prevention of human papillomavirus-related diseases. 2019;53(8):761–803.
   PubMedGoogle Scholar
• Ma D, Wei LH, Xie X, Hetal KB. Chinese expert consensus on clinical application of human papillomavirus vaccine. Chin J Front Med Sci Electron Edition. 2021;13:112.
   Google Scholar
• Cervical Cancer Diagnosis and Treatment Guidelines. 2022. [accessed 2024 Jan]. http://www.nhc.gov.cn/yzygj/s7659/202204/a0e67177df1f439898683e1333957c74/files/361f086b71214c4e8336fa7d251dc020.pdf.
   Google Scholar
• Cervical Cancer Prevention and Treatment Committee of Guangdong Preventive Medicine Association. Guangdong expert consensus on HPV vaccine application to eliminate cervical cancer Chinese language. J Chin Physician. 2021(9):1303–15.
   Google Scholar
• Gynecological Oncology Society of Chinese Medical Association; Chinese Society for Colposcopy and Cervical Pathology. Chinese expert consensus on clinical application of human papilloma virus vaccine. Chin J Clin Obstet Gynecol. 2021;22(2):1–12.
   Google Scholar
• Yangtze River Delta Cervical Cancer and Female Lower Genital Tract Infection Prevention and Control Alliance. Yangtze River Delta Immunization Integration Working Group. Expert consensus on standardized construction of human papilloma virus vaccination consultation clinics. J Multidiscip Cancer Manag. 2023;9(2):61–6.
   Google Scholar
• Branch of Cancer Prevention and Control. Chinese Preventive Medicine Association, Chinese Obstetrics and Gynecology Association Colposcopy and Cervical Neoplasia Committee, Chinese Society of Colposcopy and Cervical Pathology of China Health Birth Science Association, Beijing Medical Doctor (Technician) Society of Laboratory Medicine. Chinese expert consensus on the use of human papillomavirus nucleic acid testing for cervical cancer screening (2022). Natl Med J China. 2023;103(16):1184–95.
   Google Scholar
• Zhang Z, Shi J, Zhang X, Guo X, Yu W. Willingness of parents of 9-to-18-year-old females in China to vaccinate their daughters with HPV vaccine. Vaccine. 2023;41(1):130–5. doi:10.1016/j.vaccine.2022.11.016.
   PubMed Web of Science ®Google Scholar
• Gao D, Zhao G, Di J, Zhang X, Wang L. Knowledge of cervical cancer and HPV, and willingness to receive HPV vaccination among 20-45-year-old women - six provinces, China, 2018. China CDC Wkly. 2023;5(9):201–5. doi:10.46234/ccdcw2023.036.
   PubMedGoogle Scholar
• Wang H, Wang X, Chen P, Xu H, Liu Y, Kang R, Zheng L, Sun X, Sun X, Zhang S, et al. Effect of health intervention via web-based education on improving information-motivation-behavioral skills related to HPV vaccination among Chinese female college students. Int J Public Health. 2023;68:1605596. doi:10.3389/ijph.2023.1605596.
   PubMed Web of Science ®Google Scholar
• Fengzhi Z, Li M, Li X, Bai H, Gao J, Liu H. Knowledge of cervical cancer prevention and treatment, and willingness to receive HPV vaccination among college students in China. BMC Public Health. 2022;22(1):2269. doi:10.1186/s12889-022-14718-0.
   PubMed Web of Science ®Google Scholar
• Xie L, Ren J, Min S, Zhu X, Xu D, Qiao K, Chen X, Liu M, Xiao Z, Tan Y, et al. Knowledge, attitude, and perception regarding HPV-related diseases and vaccination among the general public in Guizhou Province of China. Vaccine. 2023;41(5):1119–31. doi:10.1016/j.vaccine.2022.12.027.
   PubMed Web of Science ®Google Scholar
• Wu H, Tong X, Wang L, Huang Y, Zhang L. HPV vaccine information, knowledge, attitude, and recommendation intention among male college students in China. Hum Vaccin Immunother. 2023;19(2):2228163. doi:10.1080/21645515.2023.2228163.
   PubMed Web of Science ®Google Scholar
• Shi ZY, Hao JQ, SJ H, Su Z, Liu SJ, Zhang X, et al. Knowledge, attitude and practice about human papillomavirus and HPV vaccine in Chinese Mainland: a meta-analysis. Cancer Res Prev Treat. 2022;49(5):464–71.
   Google Scholar
• Zhang X, Su Z, Xu HF. Knowledge on and willingness to receive human papillomavirus vaccination among child-bearing women in mainland China, 2009 – 2016: a pooled analysis. Chin J Public Health. 2021;37:1726–30.
   Google Scholar
• Song D, Liu P, Wu D, Zhao F, Wang Y, Zhang Y. Knowledge and attitudes towards human papillomavirus vaccination (HPV) among healthcare providers involved in the governmental free HPV vaccination program in Shenzhen, Southern China. Vaccines. 2023;11(5):997. doi:10.3390/vaccines11050997.
   Web of Science ®Google Scholar
• Mao Y, Zhao Y, Zhang L, Li J, Abdullah AS, Zheng P, Wang F. Frequency of health care provider recommendations for HPV vaccination: a survey in three large cities in China. Front Public Health. 2023;11:1203610. doi:10.3389/fpubh.2023.1203610.
   PubMed Web of Science ®Google Scholar
• Lin Y, Su Z, Chen F, Zhao Q, Zimet GD, Alias H, He S, Hu Z, Wong LP. Chinese mothers’ intention to vaccinate daughters against human papillomavirus (HPV), and their vaccine preferences: a study in Fujian Province. Hum Vaccin Immunother. 2021;17(1):304–15. doi:10.1080/21645515.2020.1756152.
   PubMed Web of Science ®Google Scholar
• Yi Y, Xiu S, Shi N, Huang Y, Zhang S, Wang Q, Yang L, Cui T, Wang Y, Shen Y, et al. Perceptions and acceptability of HPV vaccination among parents of female adolescents 9–14 in China: a cross-sectional survey based on the theory of planned behavior. Hum Vaccin Immunother. 2023;19:2225994. doi:10.1080/21645515.2023.2225994.
   PubMed Web of Science ®Google Scholar
• Guo Q, Zhou W, Wen X, Lu J, Lu X, Lu Y. Discrepancy of human papillomavirus vaccine uptake and intent between girls 9-14 and their mothers in a pilot region of Shanghai, China. Hum Vaccin Immunother. 2022;18(6):2132801. doi:10.1080/21645515.2022.2132801.
   PubMed Web of Science ®Google Scholar
• Chen L, Sun X, Luo J, Zhang Y, Ha Y, Xu X, Tao L, Mu X, Gao S, Han Y, et al. A case-control study on factors of HPV vaccination for mother and daughter in China. Vaccines. 2023;11(5):976. doi:10.3390/vaccines11050976.
   Web of Science ®Google Scholar
• Chan DNS, Lee PPK, So WKW. Exploring the barriers and facilitators influencing human papillomavirus vaccination decisions among South Asian and Chinese mothers: a qualitative study. J Racial Ethn Health Disparities. 2023;1–13. doi:10.1007/s40615-023-01623-4.
   PubMed Web of Science ®Google Scholar
• Xie H, Zhu HY, Jiang NJ, Yin YN. Awareness of HPV and HPV vaccines, acceptance to vaccination and its influence factors among parents of adolescents 9 to 18 years of age in China: a cross-sectional study. J Pediatr Nurs. 2023;71:73–8. doi:10.1016/j.pedn.2023.03.007.
   PubMed Web of Science ®Google Scholar
• Yin X, Zhang M, Wang F, Huang Y, Niu Y, Ge P, Yu W, Wu Y. A national cross-sectional study on the influencing factors of low HPV vaccination coverage in mainland China. Front Public Health. 2023;10:1064802. doi:10.3389/fpubh.2022.1064802.
   PubMedGoogle Scholar
• Shao X, Lu X, Zhou W, Huang W, Lu Y. HPV vaccination behavior, vaccine preference, and health beliefs in Chinese female health care workers: a nationwide cross-sectional study. Vaccines. 2023;11(8):1367. doi:10.3390/vaccines11081367.
   Web of Science ®Google Scholar
• Lu X, Ji M, Wagner AL, Huang W, Shao X, Zhou W, et al. Willingness to pay for HPV vaccine among female health care workers in a Chinese nationwide survey. BMC Health Serv Res. 2022;22(1):1324. doi:10.1186/s12913-022-08716-6.
   PubMed Web of Science ®Google Scholar
• Zhou L, Gu B, Wang J, Liu G, Zhang X. Human papillomavirus vaccination at the national and provincial levels in China: a cost-effectiveness analysis using the PRIME model. BMC Public Health. 2022;22(1):777. doi:10.1186/s12889-022-13056-5.
   PubMed Web of Science ®Google Scholar
• Shi W, Cheng X, Wang H, Zang X, Chen T. Cost-effectiveness of human papillomavirus vaccine in China: a systematic review of modelling studies. BMJ Open. 2021;11(12):e052682. doi:10.1136/bmjopen-2021-052682.
   PubMed Web of Science ®Google Scholar
• Zou M, Liu H, Wang M, Zou Z, Zhang L. Vaccinating women previously treated for human papillomavirus-related cervical precancerous lesions is highly cost-effective in China. Front Immunol. 2023;14:1119566. doi:10.3389/fimmu.2023.1119566.
   PubMed Web of Science ®Google Scholar
• Xia C, Xu X, Zhao X, Hu S, Qiao Y, Zhang Y, Hutubessy R, Basu P, Broutet N, Jit M, et al. Effectiveness and cost-effectiveness of eliminating cervical cancer through a tailored optimal pathway: a modeling study. BMC Med. 2021;19(1):62. doi:10.1186/s12916-021-01930-9.
   PubMed Web of Science ®Google Scholar
• Guo JM, Zheng B, Li N, Lin BJ, Chen TT, He X, et al. Human papillomavirus vaccine prevents cervical cancer in Chinese women: a systematic review of pharmacoeconomic evaluation. Chin J Mod Appl Pharm. 2021;38(4):445–52.
   Google Scholar
• World Health Organization. WHO updates recommendations on HPV vaccination schedule. World Health Organization; 2022Dec 20 [accessed 2024 Feb]. https://www.who.int/news/item/20-12-2022-WHO-updates-recommendations-on-HPV-vaccination-schedule.
   Google Scholar